On January 13, 2025, Roivant Sciences presented at the J.P. Morgan Healthcare Conference, outlining its strategic vision and key catalysts for the year. The company highlighted its 'Vant' model, which focuses on accelerating drug development through specialized subsidiaries. This approach aims to bring innovative therapies to market efficiently.
Roivant emphasized several near-term catalysts, including potential data readouts for batoclimab in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by March 2025. Additionally, data for Thyroid Eye Disease (TED) is expected in the second half of 2025. The company also anticipates five more IMVT-1402 indications by March 2026, building on its five cleared Investigational New Drug (IND) applications.
The presentation also detailed the expected registrational readout for brepocitinib in dermatomyositis (DM) in the second half of 2025, which could position it as the first novel oral DM drug. Furthermore, Roivant provided updates on its LNP patent litigation against Moderna, with a U.S. jury trial scheduled for September 2025, and ongoing progress expected in the Pfizer/BioNTech case.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.